Depletion of Mirk/dyrk1B enabled low levels of cisplatin to elevate ROS levels to toxic levels in ovarian cancer cells grown under adherent conditions (11), so cisplatin was selected. This evidence concerns the gene DYRK1B and ovarian carcinoma.